晶华微(688130) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 29,284,068.48, a decrease of 45.54% year-on-year[5]. - Net profit attributable to shareholders was CNY 2,963,461.60, down 87.62% compared to the same period last year[5]. - Basic and diluted earnings per share were both CNY 0.04, a decrease of 91.67% year-on-year[6]. - Total operating revenue for Q1 2023 was ¥29,284,068.48, a decrease of 45.5% compared to ¥53,775,932.10 in Q1 2022[24]. - Net profit for Q1 2023 was ¥2,963,461.60, down 87.6% from ¥23,933,649.32 in Q1 2022[25]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.04, compared to ¥0.48 in Q1 2022[26]. Research and Development - R&D expenses totaled CNY 15,442,171.34, representing a 99.35% increase year-on-year, accounting for 52.73% of operating revenue, an increase of 38.33 percentage points[6][8]. - Research and development expenses surged to ¥15,442,171.34, an increase of 99.1% from ¥7,746,227.16 in Q1 2022[24]. - The company had a total of 149 employees at the end of the reporting period, with R&D personnel increasing by 15.73% compared to the end of 2022[8]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,323,559,896.57, a decrease of 1.71% from the end of the previous year[6]. - Total assets decreased to ¥1,323,559,896.57 from ¥1,346,539,258.96, a decline of 1.7%[23]. - Total liabilities decreased significantly from ¥36,248,780.98 to ¥9,153,690.85, a reduction of 74.8%[22]. - Current liabilities totaled ¥8,172,797.07, down from ¥35,168,354.51, indicating a decrease of 76.8%[22]. Cash Flow - In Q1 2023, the cash inflow from operating activities was CNY 12,755,089.71, a decrease of 60.5% compared to CNY 32,327,446.93 in Q1 2022[27]. - The net cash flow from operating activities was -CNY 18,636,533.46, an improvement from -CNY 21,696,227.17 in Q1 2022[28]. - Cash inflow from investment activities was CNY 190,313,277.95, a decrease of 23.6% from CNY 249,146,488.79 in Q1 2022[28]. - The net cash flow from investment activities was -CNY 110,898,577.25, worsening from -CNY 31,442,353.64 in the previous year[28]. - The total cash and cash equivalents at the end of Q1 2023 were CNY 851,542,530.92, compared to CNY 220,386,470.23 at the end of Q1 2022[29]. - The company experienced a net decrease in cash and cash equivalents of -CNY 131,425,056.06 in Q1 2023, compared to -CNY 55,236,377.36 in Q1 2022[29]. Revenue Segments - The gross margin for the main business was 67.49%, remaining stable despite the revenue decline[7]. - The revenue from health parameter chips increased significantly, rising from 3.88% of total revenue in 2022 to 15.75% in Q1 2023[7]. - Revenue from industrial control chips grew by 23.76% year-on-year due to increased domestic substitution demand and enhanced customer outreach[7]. Corporate Changes - The company plans to liquidate its wholly-owned subsidiary Shenzhen Jingjiahua Electronics Co., Ltd. and establish a new branch in Shenzhen[18]. - The company has appointed new senior management, including a new board secretary and financial director, effective from March 9, 2023[16]. - The company’s initial public offering (IPO) included a total of 654,669 shares that became tradable on January 30, 2023, representing 0.98% of the total share capital[15]. - The top ten unrestricted shareholders include notable names such as Zhou Lingsong and Peng Yongchang, with holdings of 304,101 and 182,746 shares respectively[14]. - The company has engaged in strategic placements and financing activities, with significant participation from institutional investors[14].